Back to Awarded Treatment Trials


Awarded Trial: 04T-504

Grant ID

04T-504

Illness

Schizophrenia

Primary Drug/Intervention

Raloxifene

Primary Dosage

60mg/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Usall-Rodie

Sample Size

36

Duration of Study Period for Each Subject

12 weeks

Outcome Measurements

SCID, PANSS, CGI, Calgary Depression Scale, Simpson Scale, GAF, Living Skills Profile

Results

Thirty-three (33) postmenopausal women with schizophrenia and prominent negative symptoms were randomized to adjunct raloxifene 60 mg or placebo for 3 months. Those on raloxifene had a significant reduction in both negative (p=0.04), positive (p=0.03), and general pathological (p=0.05) symptoms.

Publication

Usall J, Huerta-Ramos E, Labad J, Cobo J, Núñez C, Creus M, Parés GG, Cuadras D, Franco J, Miquel E, Reyes JC, Roca M; RALOPSYCAT Group. Raloxifene as an Adjunctive Treatment for Postmenopausal Women with Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Trial. J Clin Psychiatry. 2001;72(11):1552-1557.

Link

http://www.ncbi.nlm.nih.gov/pubmed/26591005

PI Name

Judith Usall-Rodie

Degree

MD

Center

San Joan de Deu-Serveis de Salut Mental

Institution

Fundacio Sant Joan de Deu

Address

c/ Santa Rosa 39-57, 4 planta

City or Town

Esplugues de Ll,

State or Province

Barcelona

Zip or Postal Code

8950

Country

Spain

Email Address

jusall@sjd-ssm.com